| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Beta-1; 3-galactosyl-O-glycosyl-glycoprotein beta-1; 6-N-acetylglucosaminyltransferase 6; EC 2.4.1.-; |
| Entrez GeneID | 644378; |
| WB Predicted band size | 45kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human GCNT6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于GCNT6抗体的3篇参考文献示例(文献为虚构模拟，仅作格式参考)：
1. **文献名称**: *GCNT6 as a novel biomarker in pancreatic ductal adenocarcinoma*
**作者**: Smith A, et al.
**摘要**: 本研究通过免疫组化(IHC)分析发现，GCNT6蛋白在胰腺导管腺癌(PDAC)组织中高表达，且与患者预后不良相关。使用特异性GCNT6抗体证实其在肿瘤细胞膜上的定位，提示其可能作为PDAC的诊断标志物。
2. **文献名称**: *Role of GCNT6 in colorectal cancer progression and chemoresistance*
**作者**: Chen L, et al.
**摘要**: 通过Western blot和免疫荧光技术，作者发现GCNT6在结直肠癌(CRC)细胞系中显著上调，并通过调控黏蛋白糖基化促进肿瘤转移。研究使用商业化GCNT6抗体验证了其在临床样本中的表达水平，并证明其与化疗耐药性相关。
3. **文献名称**: *GCNT6-mediated glycosylation in gastric cancer stem cells*
**作者**: Tanaka K, et al.
**摘要**: 该研究利用GCNT6抗体进行流式细胞术分选，发现GCNT6高表达的胃癌细胞具有干性特征。实验表明，抑制GCNT6表达可降低肿瘤球形成能力，揭示其在胃癌干细胞维持中的关键作用。
4. **文献名称**: *Development and validation of a monoclonal antibody against human GCNT6*
**作者**: Wang X, et al.
**摘要**: 本文报道了一种新型抗GCNT6单克隆抗体的开发，并通过ELISA、免疫组化和蛋白质印迹验证其特异性。该抗体成功应用于乳腺癌组织微阵列分析，显示GCNT6表达与肿瘤分级呈正相关。
(注：以上文献信息为模拟生成，实际研究中请通过PubMed或学术数据库查询真实文献。)
GCNT6 (Glucosaminyl (N-acetyl) Transferase Family Member 6) is an enzyme belonging to the β-1.6-N-acetylglucosaminyltransferase family, which catalyzes the formation of branched O-glycan structures, particularly core 2 and core 4 glycans, on mucin-type glycoproteins. These post-translational modifications play critical roles in cell adhesion, signaling, and immune responses. Dysregulation of GCNT6 has been implicated in cancer progression, as altered O-glycosylation patterns can promote tumor cell invasion, metastasis, and immune evasion.
GCNT6 antibodies are immunological tools developed to detect and study the expression, localization, and function of the GCNT6 protein in biological samples. They are widely used in research applications such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate GCNT6’s role in diseases, particularly cancers like colorectal, breast, and pancreatic carcinomas. Studies have shown that GCNT6 is overexpressed in certain malignancies, correlating with aggressive phenotypes and poor prognosis. Its expression in normal tissues is relatively restricted, making it a potential biomarker or therapeutic target.
These antibodies are critical for elucidating GCNT6’s contribution to glycosylation-dependent mechanisms in pathophysiology. Commercial GCNT6 antibodies are typically validated for specificity and sensitivity, enabling researchers to explore its diagnostic or therapeutic relevance in precision medicine.
×
